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Henoch-Schönlein purpura (HSP) was first described more than 200 years ago by Heberdon. It is the most common systemic 
vasculitis of  childhood. Short and long term outcomes 
of  HSP is generally favorable, with complete and 
spontaneous resolution of  symptoms (1-3).
Renal involvement occurs in 40%-60% of  pediatric 
patients within 4 to 6 weeks of  the initial presentation 
(1). It is the major cause of  mortality and morbidity in 
children with HSP (2) and prognosis is mainly dependent 
upon the severity of  renal involvement (4).
Majority of  patients with Henoch-Schönlein purpura 
nephritis (HSN) have a mild disease, presenting with 
hematuria and/or low-grade proteinuria, with a high 
recovery rate. A small percentage of  patients present 
with nephrotic syndrome or renal function impairment 
(1,2).
A direct correlation has been suggested between the 
intensity of  clinical manifestations, histopathologic 
grading, and renal outcome in HSN. There is a positive 
relationship between the severity of  proteinuria, 
nephrotic syndrome and acute nephritis with both 
pathologic grading and scoring, particularly crescent 
formation, endocapillary proliferation, and tubular 
atrophy (2).
It has been suggested that older age at presentation, 
hypertension, increased serum creatinine, early onset 
nephritic, mixed nephritic–nephrotic syndrome at 
the onset of  disease, extensive crescents, severity of 
glomerular necrosis and sclerosis, with tubulointerstitial 
damage are the major risk factors of  renal impairment in 
these patients (2,5).
Chronic kidney disease occurs in almost 20% of  children 
admitted to the tertiary care centers (4). About 1%-7% of 
unselected patients with HSN may progress to end-stage 
renal disease by 20 years after diagnosis (1,6). However, 
early diagnosis, along with appropriate treatment and 
timely management improve eventual renal outcome in 
these patients (3).
There is no consensus for the treatment of  HSN (1) and 
the most effective treatment remains controversial (7). It 
has been suggested that early corticosteroids treatment 
may not prevent the development of  HSN and should 
not be routinely recommended (8,9).
Renal biopsy or immunosuppressive treatments is not 
recommended in patients with mild renal symptoms 
such as microhematuria, mild proteinuria and normal 
renal function which needs to regular follow up for the 
early detection of  renal deterioration (1,3).
Data on the treatment of  severe HSN are controversial 
and scarce (10). KDIGO guidelines recommended early 
treatment with angiotensin converting enzyme inhibitors 
(ACE-I) or angiotensin receptor blockers (ARBs) in 
patients with persistent proteinuria (1), to improve long 
term renal outcome independent of  histologic lesions 
(11). A 6-month course of  corticosteroid therapy is 
recommended in those with persistent proteinuria and 
glomerular filtration rate >50 mL/min per 1.73 m2.
Early immunosuppressive therapy with high dose 
corticosteroids, cyclophosphamide, azathioprine (1) 
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calcineurin inhibitors (12), mycophenolate mofetil 
(MMF) (13), rituximab (3), mizoribine or methotrexate 
(1) have been suggested in patients with significant 
kidney involvement (proteinuria in nephrotic range 
and/or progressive kidney impairment) (3). The main 
objectives of  immunosuppressive treatments are 
prevention of  irreversible glomerular fibrosis with 
increasing proteinuria and improvement long term renal 
outcome (5,14).
In addition, combined immunosuppressive treatments 
with warfarin, dipyridamole, acetylsalicylic acid, 
tonsillectomy for eradication of  chronic bacterial 
infections, hemoperfusion for elimination of  immune 
mediators (3), intravenous immunoglobulin (IVIG) 
(5), plasma exchange for removal of  inflammatory 
and procoagulant circulating complexes, antiplatelet 
drugs and vitamins have been suggested for treatment 
of  HSN. However, there is not enough evidence about 
increased efficacy of  immune suppression or multiple-
drug treatment in children with severe HSN (1).
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